Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure

Nature Medicine

Volumn 13, Issue 3, 2007, Pages 315-323

  Lymperopoulos, Anastasios ^a,b   Rengo, Giuseppe ^a,b   Funakoshi, Hajime ^a   Eckhart, Andrea D ^a   Koch, Walter J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRIMONIDINE; G PROTEIN COUPLED RECEPTOR KINASE 2; MOXONIDINE;

ADRENAL GLAND; ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UPREGULATION;

ADRENAL GLANDS; ADRENOCORTICAL HYPERFUNCTION; ANIMALS; BETA-ADRENERGIC RECEPTOR KINASE; CELLS, CULTURED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE, CONGESTIVE; MALE; MICE; MICE, TRANSGENIC; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION;

EID: 33847728682     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1553     Document Type: Article

References (40)

1. Rich, M.W. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J. Am. Geriatr. Soc. 45, 968-974 (1997).
2. Cohn, J.N. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819-823 (1984).
3. Port, J.D. & Bristow, M.R. Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. 33, 887-905 (2001).
4. Rockman, H.A. et al. Seven-transmembrane-spanning receptors and heart function. Nature 415, 206-212 (2002).
5. Hoffman, B.B. & Taylor, P. Neurotransmission: the autonomic and somatic motor nervous system. in Goodman & Gilman's: The Pharmacological Basis of Therapeutics 10th edn. (eds. Hardman, J.G. & Limbird, L.E.) Ch. 6, 115-154 (McGraw-Hill, New York, 2001).
6. Young, J.B. & Landsberg, L. Catecholamines and the adrenal medulla. in Williams Textbook of Endocrinology 9th edn. (eds. Wilson, J.D., Foster, D.W., Kronenberg, H.M. & Larsen, P.R.) Ch. 17, 665-728 (W.B. Saunders, Philadelphia, 1998).
7. Hata, J.A. et al. Genetic manipulation of myocardial β-adrenergic receptor activation and desensitization. J. Mol. Cell. Cardiol. 37, 11-21 (2004).
8. Bylund, D.B. et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46, 121-136 (1994).
9. Link, R.E. et al. Cardiovascular regulation in mice lacking a2-adrenergic receptor subtypes b and c. Science 273, 803-805 (1996).
10. MacMillan, L.B. et al. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273, 801-803 (1996).
11. 2-adrenoceptor subtypes. Mol. Endocrinol. 17, 1640-1646 (2003).
12. 2- adrenergic receptors regulate sympathetic neurotransmission. Nature 402, 181-184 (1999).
13. Brede, M. et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106, 2491-2496 (2002).
14. Brum, P.C. et al. Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am. J. Physiol. Heart Circ. Physiol. 283, H1838-H1845 (2002).
15. 2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
16. Small, K.M. et al. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43, 381-411 (2003).
17. Neumeister, A. et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoceptor gene polymorphism in healthy humans. Pharmacogenet. Genomics 15, 143-149 (2005).
18. Iaccarino, G. et al. Elevated myocardial and lymphocyte GRK2 expression in human heart failure. Eur. Heart J. 26, 1752-1758 (2005).
19. Harding, V.B. et al. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc. Natl. Acad. Sci. USA 98, 5809-5814 (2001).
20. Most, P. et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J. Clin. Invest. 114, 1550-1563 (2004).
21. Jewell-Motz, E.A. & Liggett, S.B. G protein-coupled receptor kinase specificity for phosphorylation and desensitization of alpha2-adrenergic receptor subtypes. J. Biol. Chem. 271, 18082-18087 (1996).
22. Kurose, H. & Lefkowitz, R.J. Differential desensitization and phosphorylation of three cloned and transfected alpha 2-adrenergic receptor subtypes. J. Biol. Chem. 269, 10093-10099 (1994).
23. Lefkowitz, R.J. & Whalen, E.J. β-arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol. 16, 162-168 (2004).
24. Wang, Q. et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304, 1940-1944 (2004).
25. Koch, W.J. et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or βARK inhibitor. Science 268, 1350-1353 (1995).
26. Zhou, Z. & Neher, E. Mobile and immobile calcium buffers in bovine adrenal chromaffin cells. J. Physiol. (Lond.) 469, 245-273 (1993).
27. Iaccarino, G. et al. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation 98, 1783-1789 (1998).
28. 1 adrenergic stimulation. Hypertension 33, 396-401 (1999).
29. Floras, J.S. The "unsympathetic" nervous system of heart failure. Circulation 105, 1753-1755 (2002).
30. Aggarwal, A. et al. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J. Am. Coll. Cardiol. 37, 1246-1251 (2001).
31. Lang, C.C. et al. Sympathoinhibitory response to clonidine is blunted in patients with heart failure. Hypertension 30, 392-397 (1997).
32. Swedberg, K. et al. The effects of moxonidine SR, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105, 1797-1803 (2002).
33. Swedberg, K. et al. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure: Moxonidine Investigators. J. Am. Coll. Cardiol. 35, 398-404 (2000).
34. Eisenhofer, G. et al. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331-349 (2004).
35. Guyenet, P.G. et al. Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites? Am. J. Physiol. 273, R1580-R1584 (1997).
36. White, D.C. et al. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc. Natl. Acad. Sci. USA 97, 5428-5433 (2000).
37. Wilson, S.P. & Kirschner, N.J. Effects of ascorbic acid, dexamethasone, and insulin on the catecholamine and opioid peptide stores of cultured adrenal medullary chromaffin cells. J. Neurosci. 3, 1971-1978 (1983).
38. Pleger, S.T. et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol. Ther. 12, 1120-1129 (2005).
39. Uhlen, S. et al. [3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur. J. Pharmacol. 343, 93-101 (1998).
40. Perry, S.J. et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298, 834-836 (2002).